Ann Esquivel1, William W Busse1, Agustin Calatroni2, Alkis G Togias3, Kristine G Grindle1, Yury A Bochkov1, Rebecca S Gruchalla4, Meyer Kattan5, Carolyn M Kercsmar6, G Khurana Hershey6, Haejin Kim7, Petra Lebeau2, Andrew H Liu8,9, Stanley J Szefler9, Stephen J Teach10, Joseph B West11, Jeremy Wildfire2, Jaqueline A Pongracic12, James E Gern1. 1. 1 University of Wisconsin, Madison, Madison, Wisconsin. 2. 2 Rho Inc. Federal Systems Division, Chapel Hill, North Carolina. 3. 3 National Institute of Allergy and Infectious Diseases, Rockville, Maryland. 4. 4 University of Texas Southwestern Medical Center, Dallas, Texas. 5. 5 Columbia University Medical Center, New York, New York. 6. 6 Cincinnati Children's Hospital, Cincinnati, Ohio. 7. 7 Henry Ford Health System, Detroit, Michigan. 8. 8 National Jewish Health, Denver, Colorado. 9. 9 Children's Hospital Colorado and University of Colorado School of Medicine, Aurora, Colorado. 10. 10 Children's National Health System, Washington, DC. 11. 11 Boston University School of Medicine, Boston, Massachussetts; and. 12. 12 Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.
Abstract
RATIONALE: Allergic inflammation has been linked to increased susceptibility to viral illnesses, but it is unclear whether this association is causal. OBJECTIVES: To test whether omalizumab treatment to reduce IgE would shorten the frequency and duration of rhinovirus (RV) illnesses in children with allergic asthma. METHODS: In the PROSE (Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations) study, we examined children with allergic asthma (aged 6-17 yr; n = 478) from low-income census tracts in eight U.S. cities, and we analyzed virology for the groups randomized to treatment with guidelines-based asthma care (n = 89) or add-on omalizumab (n = 259). Weekly nasal mucus samples were analyzed for RVs, and respiratory symptoms and asthma exacerbations were recorded over a 90-day period during the fall seasons of 2012 or 2013. Adjusted illness rates (illnesses per sample) by treatment arm were calculated using Poisson regression. MEASUREMENTS AND MAIN RESULTS:RVs were detected in 97 (57%) of 171 exacerbation samples and 2,150 (36%) of 5,959 nonexacerbation samples (OR, 2.32; P < 0.001). Exacerbations were significantly associated with detection of rhinovirus C (OR, 2.85; P < 0.001) and rhinovirus A (OR, 2.92; P < 0.001), as well as, to a lesser extent, rhinovirus B (OR, 1.98; P = 0.019). Omalizumab decreased the duration of RV infection (11.2 d vs. 12.4 d; P = 0.03) and reduced peak RV shedding by 0.4 log units (95% confidence interval, -0.77 to -0.02; P = 0.04). Finally, omalizumab decreased the frequency of RV illnesses (risk ratio, 0.64; 95% confidence interval, 0.49-0.84). CONCLUSIONS: In children with allergic asthma, treatment with omalizumab decreased the duration of RV infections, viral shedding, and the risk of RV illnesses. These findings provide direct evidence that blocking IgE decreases susceptibility to RV infections and illness. Clinical trial registered with www.clinicaltrials.gov (NCT01430403).
RCT Entities:
RATIONALE: Allergic inflammation has been linked to increased susceptibility to viral illnesses, but it is unclear whether this association is causal. OBJECTIVES: To test whether omalizumab treatment to reduce IgE would shorten the frequency and duration of rhinovirus (RV) illnesses in children with allergic asthma. METHODS: In the PROSE (Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations) study, we examined children with allergic asthma (aged 6-17 yr; n = 478) from low-income census tracts in eight U.S. cities, and we analyzed virology for the groups randomized to treatment with guidelines-based asthma care (n = 89) or add-on omalizumab (n = 259). Weekly nasal mucus samples were analyzed for RVs, and respiratory symptoms and asthma exacerbations were recorded over a 90-day period during the fall seasons of 2012 or 2013. Adjusted illness rates (illnesses per sample) by treatment arm were calculated using Poisson regression. MEASUREMENTS AND MAIN RESULTS: RVs were detected in 97 (57%) of 171 exacerbation samples and 2,150 (36%) of 5,959 nonexacerbation samples (OR, 2.32; P < 0.001). Exacerbations were significantly associated with detection of rhinovirus C (OR, 2.85; P < 0.001) and rhinovirus A (OR, 2.92; P < 0.001), as well as, to a lesser extent, rhinovirus B (OR, 1.98; P = 0.019). Omalizumab decreased the duration of RV infection (11.2 d vs. 12.4 d; P = 0.03) and reduced peak RV shedding by 0.4 log units (95% confidence interval, -0.77 to -0.02; P = 0.04). Finally, omalizumab decreased the frequency of RV illnesses (risk ratio, 0.64; 95% confidence interval, 0.49-0.84). CONCLUSIONS: In children with allergic asthma, treatment with omalizumab decreased the duration of RV infections, viral shedding, and the risk of RV illnesses. These findings provide direct evidence that blocking IgE decreases susceptibility to RV infections and illness. Clinical trial registered with www.clinicaltrials.gov (NCT01430403).
Authors: Desmond W Cox; Joelene Bizzintino; Giovanni Ferrari; Siew Kim Khoo; Guicheng Zhang; Siobhan Whelan; Wai Ming Lee; Yury A Bochkov; Gary C Geelhoed; Jack Goldblatt; James E Gern; Ingrid A Laing; Peter N Le Souëf Journal: Am J Respir Crit Care Med Date: 2013-12-01 Impact factor: 21.405
Authors: Kazuyuki Nakagome; Yury A Bochkov; Shamaila Ashraf; Rebecca A Brockman-Schneider; Michael D Evans; Thomas R Pasic; James E Gern Journal: J Allergy Clin Immunol Date: 2014-03-14 Impact factor: 10.793
Authors: G P Rakes; E Arruda; J M Ingram; G E Hoover; J C Zambrano; F G Hayden; T A Platts-Mills; P W Heymann Journal: Am J Respir Crit Care Med Date: 1999-03 Impact factor: 21.405
Authors: Michelle A Gill; Gagan Bajwa; Tiffany A George; Caroline C Dong; Irene I Dougherty; Nan Jiang; Vanthaya N Gan; Rebecca S Gruchalla Journal: J Immunol Date: 2010-04-21 Impact factor: 5.422
Authors: Hans Bisgaard; Mette Northman Hermansen; Klaus Bønnelykke; Jakob Stokholm; Florent Baty; Nanna Lassen Skytt; Julia Aniscenko; Tatiana Kebadze; Sebastian L Johnston Journal: BMJ Date: 2010-10-04
Authors: A L Duff; E S Pomeranz; L E Gelber; G W Price; H Farris; F G Hayden; T A Platts-Mills; P W Heymann Journal: Pediatrics Date: 1993-10 Impact factor: 7.124
Authors: Gang Chen; Thomas R Korfhagen; Christopher L Karp; Soren Impey; Yan Xu; Scott H Randell; Joseph Kitzmiller; Yutaka Maeda; Hans Michael Haitchi; Anusha Sridharan; Albert P Senft; Jeffrey A Whitsett Journal: Am J Respir Crit Care Med Date: 2014-02-01 Impact factor: 21.405
Authors: Frederick G Hayden; Darrell T Herrington; Teresa L Coats; Kenneth Kim; Ellen C Cooper; Stephen A Villano; Siyu Liu; Spencer Hudson; Daniel C Pevear; Marc Collett; Mark McKinlay Journal: Clin Infect Dis Date: 2003-06-06 Impact factor: 9.079
Authors: Kohei Hasegawa; Jonathan M Mansbach; Yury A Bochkov; James E Gern; Pedro A Piedra; Cindy S Bauer; Stephen J Teach; Susan Wu; Ashley F Sullivan; Carlos A Camargo Journal: JAMA Pediatr Date: 2019-06-01 Impact factor: 16.193
Authors: Peter W Heymann; Thomas A E Platts-Mills; Judith A Woodfolk; Larry Borish; Deborah D Murphy; Holliday T Carper; Mark R Conaway; John W Steinke; Lyndsey Muehling; W Gerald Teague; Joshua L Kennedy; Anne-Marie Irani; Matthew D McGraw; Stephen V Early; Lisa M Wheatley; Amy P Adams; Ronald B Turner Journal: J Allergy Clin Immunol Date: 2020-02-01 Impact factor: 10.793
Authors: Kathryn McCauley; Juliana Durack; Ricardo Valladares; Douglas W Fadrosh; Din L Lin; Agustin Calatroni; Petra K LeBeau; Hoang T Tran; Kei E Fujimura; Brandon LaMere; Geil Merana; Kole Lynch; Robyn T Cohen; Jacqueline Pongracic; Gurjit K Khurana Hershey; Carolyn M Kercsmar; Michelle Gill; Andrew H Liu; Haejin Kim; Meyer Kattan; Stephen J Teach; Alkis Togias; Homer A Boushey; James E Gern; Daniel J Jackson; Susan V Lynch Journal: J Allergy Clin Immunol Date: 2019-06-13 Impact factor: 10.793
Authors: Elena Goleva; Denise C Babineau; Michelle A Gill; Leisa P Jackson; Baomei Shao; Zheng Hu; Andrew H Liu; Cynthia M Visness; Christine A Sorkness; Donald Y M Leung; Alkis Togias; William W Busse Journal: J Allergy Clin Immunol Date: 2018-07-27 Impact factor: 10.793
Authors: Kohei Hasegawa; Tadahiro Goto; Atsushi Hirayama; Federico R Laham; Jonathan M Mansbach; Pedro A Piedra; Carlos A Camargo Journal: Pediatr Infect Dis J Date: 2019-08 Impact factor: 2.129